In the news release, Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026 in Boston, issued 29-Oct-2026 by Nanoscope Therapeutics over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026 in Boston
- Sessions to address scientific, regulatory, commercial, and market access path for MOGENRY® (sonpiretigene isteparvovec; MCO-010), a one-time, in-office, mutation-agnostic, optogenetic gene therapy currently under FDA and PMDA review
- Co-Founder, CEO Sulagna Bhattacharya to join Keynote Panel on navigating the cell and gene therapy landscape and driving market success; Co-Founder, President Samarendra Mohanty to join Keynote Panel on evolution and future outlook for investment in advanced therapies; and present on disease-agnostic gene therapy for neurodegenerative conditions
- EVP, Value & Access Ramesh Arjunji to present on building early evidence to support access and pricing for rare diseases and joining panel on expanding access to cell and gene therapies; Ananta Ayyagari, Sr. Director-Regulatory, to present on Navigating Global Regulatory Filings
DALLAS, Oct. 30, 2026 /PRNewswire/ — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that members of its leadership team will participate in Advanced Therapies USA 2026, taking place November 4–5, 2026, at the Hynes Convention Center in Boston, Massachusetts. Advanced Therapies USA convenes cell and gene therapy developers, manufacturers, investors, and commercial leaders to address the challenges of bringing advanced therapies from the clinic to patients.
Presentation Details:
Session: Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success
Format: Keynote Panel Discussion
Moderator: Miguel Forte, CEO, Kiji Therapeutics, and President, ISCT
Panelist: Sulagna Bhattacharya, MBA, Co-Founder and Chief Executive Officer
Date & Time: Wednesday, November 4, 2026, 9:45 AM ET
Location: Keynote/Theatre 1
Session: Disease-Agnostic Gene Therapy for Neurodegenerative Conditions
Format: Presentation
Track: Gene Therapy (Track 4)
Presenter: Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer
Date & Time: Wednesday, November 4, 2026, 11:30 AM ET
Location: Hall D, Level 2
Session: Starting Early to Develop Evidence to Support Access & Pricing for Rare Diseases
Format: Presentation
Track: Evidence, Pricing & Access (Track 8)
Presenter: Ramesh Arjunji, PhD, Executive Vice President, Value & Access
Date & Time: Wednesday, November 4, 2026, 1:55 PM ET
Location: Room 209
Session: Overcoming Barriers and Expanding Access to Cell and Gene Therapies
Format: Panel Discussion
Track: Evidence, Pricing & Access (Track 8)
Moderator: Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FDA
Panelist: Ramesh Arjunji, Executive Vice President, Value & Access
Date & Time: Wednesday, November 4, 2026, 5:10 PM ET
Location: Room 209
Session: Where’s the Money? Evolution And Future Outlook for Investment in Advanced Therapies
Format: Keynote Panel Discussion
Moderator: Sven Kili, Partner, Saisei Ventures
Panelist: Samarendra Mohanty, PhD, Co-Founder and President
Date & Time: Thursday, November 5, 2026, 9:35 AM ET
Location: Keynote/Theatre 1
Session: Navigating Global Regulatory Filings
Format: Presentation
Speaker: Ananta Ayagari, PhD, Sr. Director of Regulatory
Date & Time: Wednesday, November 5, 2026, 4:20 PM ET
Location: Room 209
Members of the Nanoscope leadership team will be available to meet with potential partners, investors, and industry stakeholders throughout the conference.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan.
About Nanoscope Therapeutics
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY, and the PMDA has accepted for priority review the Company’s NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.
Contact:
Nanoscope Therapeutics, Inc
+1 (817) 857-1186
PR@nanostherapeutics.com
Correction: An incorrect version of the release was originally issued. This is the complete and correct release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-to-participate-in-advanced-therapies-usa-2026-in-boston-302923034.html
SOURCE Nanoscope Therapeutics
